Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

1(25.0%)

N/A

1(25.0%)

4Total

Phase 1(2)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT04702451Not ApplicableCompleted

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

Role: collaborator

NCT04158713Phase 3Completed

Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2)

Role: collaborator

NCT02091310Phase 1Completed

Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

Role: collaborator

NCT01258816Phase 1Completed

The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

Role: collaborator

All 4 trials loaded